Journal
CURRENT VASCULAR PHARMACOLOGY
Volume 19, Issue 6, Pages 634-642Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1570161119666210111123621
Keywords
Peripheral artery disease; lipid-lowering therapy; statins; low-density lipoprotein-cholesterol; target attainment; car-diovascular risk
Funding
- AMGEN
Ask authors/readers for more resources
This study analyzed lipid-lowering therapy (LLT) in symptomatic PAD patients, finding that the majority of patients were on statin therapy, but there is still room for improvement. Patients with additional vascular region affected received more intensive treatment and had lower LDL-C levels.
Background: Patients with peripheral artery disease (PAD) fall under the category of a very high cardiovascular risk. Although consequent lipid-lowering therapy (LLT) is advised, only sparse data on attained target level in PAD exists. Objectives: We aimed to analyse contemporary guideline recommendations for LLT in symptomatic PAD patients. Methods: A monocentric, prospective, observational study involving 200 symptomatic PAD patients was conducted. Guideline target level attainment and LLT were analysed between 2017 and 2019. Results: Overall, 78.5% of the patients were on statin therapy, mainly of high intensity, with atorvastatin in 50% and rosuvastatin in 33% of the cases. The average statin dosage adjusted for simvastatin was 55 mg/d. Low density lipoprotein-cholesterol (LDL-C) was <1.8 mmol/L in 53% and <1.4 mmol/L in 34% of the cases. Mean LDL-C levels were at 1.85 +/- 0.88 mmol/L. We observed no difference in the treatment and the target level attainment of patients with a stable PAD (intermittent claudication) or chronic critical PAD. However, patients with >= 1 vascular region affected (i.e., coronary and/or cerebrovascular) were treated more intensively and had lower LDL-C levels than patients with PAD alone. Conclusion: It appears that there are more awareness and improvement of previously documented undertreatment of LDL-C levels in symptomatic PAD patients. Although statin treatment is initiated in the majority of patients, our findings call for a continuously intensified LLT in symptomatic PAD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available